CP 91,149
CAY-17709-25 25 mg
Data Sheet: 
SDS:
SDS:
CAS
186392-40-5
Formulation
A crystalline solid
Purity
≥98%
MW
399,9
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
An inhibitor of LGPa, MGPa, and MGPb (IC50s = 0.13, 0.2, and 0.3 μM, respectively, in the presence of glucose); inhibits glucagon-stimulated glycogenolysis in primary human hepatocytes (IC50 = 2.1 μM) and increases glycogen synthesis in rat hepatocytes at a concentration of 2.5 μM in the presence of 5 mM glucose; inhibits brain GP (IC50 = 0.5 μM) and glycogen accumulation and proliferation of A549 NSCLC cells that express endogenous brain GP (30 μM); lowers plasma glucose level in diabetic ob/ob mice within 3 hours of administration without producing hypoglycemia, but has no effect on normoglycemic, non-diabetic mice (25 mg/kg, p.o.)
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
